| [1] |
Younossi ZM, Koenig AB, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64:73-84.
|
| [2] |
Willner IR, Waters B, Patil SR, et al.Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol,2001,96:2957-2961.
|
| [3] |
Caussy C, Soni M, Cui J, Bettencourt R, et al.Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest,2017,127:2697-2704.
|
| [4] |
Valenti LVC, Baselli GA.Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update. Curr Pharm Des,2018,24:4566-4573.
|
| [5] |
Romeo S, Kozlitina J, Xing C, et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet,2008,40:1461-1465.
|
| [6] |
Sookoian S, Pirola CJ.Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology,2011,53:1883-1894.
|
| [7] |
Buch S, Stickel F, Trepo E, Way M, et al.A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet,2015,47:1443-1448.
|
| [8] |
BasuRay S, Smagris E, Cohen JC, et al. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology, 2017,66:1111-1124.
|
| [9] |
Luukkonen PK, Nick A, Holtta-Vuori M, et al.Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight,2019,4.
|
| [10] |
Yang A, Mottillo EP, Mladenovic-Lucas L, et al.Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. Nat Metab,2019,1:560-569.
|
| [11] |
Pericleous M, Kelly C, Wang T, et al.Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol Hepatol,2017,2:670-679.
|
| [12] |
Carter A, Brackley SM, Gao J, et al.The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD. J Hepatol,2019,70:142-150.
|
| [13] |
Yang J, Trepo E, Nahon P, et al.A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology, 2019,70:231-240.
|
| [14] |
Ma Y, Belyaeva OV, Brown PM, et al.17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology,2019,69:1504-1519.
|
| [15] |
Eslam M, Valenti L, Romeo S.Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol,2018,68:268-279.
|
| [16] |
Pirola CJ, Flichman D, Dopazo H, et al.A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis. Hepatol Commun,2018,2:1030-1036.
|
| [17] |
Dongiovanni P, Meroni M, Mancina RM, et al.Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatol Commun,2018,2:666-675.
|
| [18] |
Welty FK.Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidoli,2014,25:161-168.
|
| [19] |
Kozlitina J, Smagris E, Stender S, et al.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet, 2014,46:352-356.
|
| [20] |
Fan Y, Lu H, Guo Y, Zhu T, et al.Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice. Gastroenterology,2016,150:1208-1218.
|
| [21] |
Sookoian S, Pirola CJ, Valenti L, et al.Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. Hepatology,2020,72:330-346.
|
| [22] |
Sookoian S, Pirola CJ.Nonalcoholic fatty liver disease and metabolic syndrome: Shared genetic basis of pathogenesis. Hepatology,2016,64:1417-1420.
|
| [23] |
Valenti L, Rametta R, Dongiovanni P, et al.Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes,2008,57:1355-1362.
|
